Status:
COMPLETED
Protocol for Women at Increased Risk of Developing Breast Cancer
Lead Sponsor:
Carol Fabian, MD
Collaborating Sponsors:
Novartis
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
A pilot study to assess the effects of six months of letrozole on breast tissue risk markers in postmenopausal women on hormone replacement therapy at high risk of developing breast cancer.
Detailed Description
A pilot study of letrozole in postmenopausal women on hormone replacement therapy at high risk of developing breast cancer. Subjects will have hyperplasia with atypia (or borderline Epithelial Hyperpl...
Eligibility Criteria
Inclusion
- evidence of hyperplasia with/without atypia upon random periareolar fine needle aspiration of breast
- on hormone replacement therapy
- postmenopausal
- increased risk of developing breast cancer based on personal or family history
- never have taken aromatase inhibitors or selective estrogen receptor modulators in last six months
- women who have a high risk of breast cancer
- older than 18 years
Exclusion
- anticoagulants
- marked breast tenderness
- pregnant or within twelve months of breast feeding/childbirth
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00291135
Start Date
January 1 2003
End Date
October 1 2008
Last Update
June 15 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160